新冠肺炎疫情防控下广东生物医药产业创新发展对策研究

Innovative Development Countermeasure Research of Guangdong Biopharmaceutical Industry under the Prevention and Control of Novel Coronavirus Pneumonia Epidemic

围绕新冠肺炎疫情防控需要,要加大生物疫苗、抗病毒创新药、检测试剂等科研攻关力度,为战胜疫病提供强大科技支撑。重点分析广东生物医药产业规模、技术水平及趋势、产业集群及重点企业,梳理广东生物医药产业存在的技术水平较低、核心技术受制于人、高端创新平台较少、医疗数据和生物样品等跨境流动体制机制障碍仍未破除等问题,并提出七条具体对策建议。

Focusing on the novel corona-virus pneumonia epidemic prevention and control needs,the research efforts of biological vaccines,anti-virus innovative drugs and testing reagents should be increased,providing strong technological support for the fight against epidemic diseases.This paper focuses on the analysis of the scale,technology level and trend,industrial clusters and key enterprises of Guangdong’s biomedical industry,and combs the problems existing in Guangdong’s biomedical industry,such as low technology level,the core technology being controlled by others,lack of high-end innovation platforms,and the obstacles of the system and mechanism of medical data and biological samples cross-border flow still remain unsolved,and puts forward seven specific countermeasures and suggestions.